Vera Therapeutics Inc. (VERA)
21.45
-0.98 (-4.37%)
At close: Apr 14, 2025, 3:59 PM
21.74
1.35%
After-hours: Apr 14, 2025, 07:56 PM EDT
-4.37% (1D)
| Bid | 21.47 |
| Market Cap | 1.37B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -152.15M |
| EPS (ttm) | -2.75 |
| PE Ratio (ttm) | -7.8 |
| Forward PE | -11.89 |
| Analyst | Buy |
| Ask | 22.05 |
| Volume | 587,230 |
| Avg. Volume (20D) | 962,373 |
| Open | 22.67 |
| Previous Close | 22.43 |
| Day's Range | 21.32 - 22.68 |
| 52-Week Range | 18.53 - 51.61 |
| Beta | 1.27 |
About VERA
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of ...
Industry Biotechnology
Sector Healthcare
IPO Date May 14, 2021
Employees 112
Stock Exchange NASDAQ
Ticker Symbol VERA
Website https://veratx.com
Analyst Forecast
According to 8 analyst ratings, the average rating for VERA stock is "Buy." The 12-month stock price forecast is $61, which is an increase of 184.38% from the latest price.
Stock Forecasts3 months ago
-6.08%
Vera Therapeutics shares are trading lower. The co...
Unlock content with
Pro Subscription
5 months ago
-9.23%
Vera Therapeutics shares are trading lower after the company announced plans to commence a public offering to issue and sell $300 million of its Class A common stock.
